Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication. Second, acquisition of chemotherapy resistance results in untreatable progressive disease. Advances in treatment of advanced ovarian cancer involve a spectrum of interventions including improvements in frontline debulking surgery and combination chemotherapy. Anti-angiogenic factors have been shown to have activity in frontline and recurrent disease while novel chemotherapeutic agents and targeted treatments are in development particularly for disease that is resistant to platinum-based chemotherapy. These developments aim to improve the progression-free and overall survival of women with advanced ovarian cancer.

Original publication




Journal article


Womens Health (Lond)

Publication Date





355 - 367


BRCA, PARP inhibitors, TP53, adjuvant chemotherapy, debulking surgery, immunotherapy, intraperitoneal chemotherapy, neoadjuvant chemotherapy, ovarian cancer, platinum resistance, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Female, Global Health, Gynecologic Surgical Procedures, Humans, Neoadjuvant Therapy, Ovarian Neoplasms, Randomized Controlled Trials as Topic, Women's Health